viernes, 20 de noviembre de 2026

Hypothalamic volume and cell-type changes in ageing and Alzheimer’s disease Doudou Yu, Jürgen Germann, Ghulam Murtaza, Kaitlyn H. Hajdarovic, Kelsey R. Babcock, Shiva Kazempour Dehkordi, Alexander C. Jackson, Ivana Delalle, Miranda E. Orr, Habil Zare, Ritambhara Singh, Michael J. MacCoss, William Stafford Noble, Andrei G. Vlassenko, Manu S. Goyal & Ashley E. Webb

https://www.nature.com/articles/s41586-026-11305-w Alterations in metabolism, stress response, sleep, circadian rhythms and neuroendocrine processes are key features of ageing and neurodegeneration1,2. These fundamental processes are regulated by the hypothalamus, yet how its functionally distinct subregions and cell types change during human ageing and Alzheimer’s disease (AD) remains largely unexplored. Here we present HypoAD, an atlas of the human hypothalamus in ageing and AD, including high-resolution magnetic resonance imaging from 458 individuals and single-nucleus RNA sequencing of 614,403 nuclei from young participants, patients with AD and age-matched non-dementia control participants. We show that hypothalamic subregions governing metabolism, stress and circadian rhythms are particularly vulnerable, showing notable changes in both volumes and gene expression during ageing and AD. At the molecular level, machine learning models identified the inflammatory response and regulators of circadian rhythms as key cellular predictors of AD. These signatures were reflected in specific cell types: microglia transitioned to a pro-inflammatory state, whereas inhibitory neurons within sleep-regulating and circadian-regulating hypothalamic subregions showed the most profound transcriptional alterations, including disruptions in ligand–receptor interactions and G-protein-coupled receptor signalling. HypoAD provides a high-resolution volumetric map and a transcriptomic atlas of the human hypothalamus in ageing and AD, relating lifestyle and behavioural changes to the relevant volumetric and molecular pathways. In addition, HypoAD provides a framework to investigate hypothalamic dysfunction and establishes a roadmap for targeted interventions aimed at mitigating physiological disruptions to potentially slow disease progression.

No hay comentarios:

Publicar un comentario